Midostaurin Improves Survival in FLT3-Mutant AML

Adding midostaurin to chemotherapy prolonged survival in younger adult patients with acute myeloid leukemia and a FLT3 mutation, according to a randomized trial.

Source: CancerNetwork - June 23, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news